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Abstract
Idiopathic autism, caused by genetic susceptibility interacting with unknown environmental triggers, has increased
dramatically in the past 25 years. Identifying environmental triggers has been difficult due to poorly understood
pathophysiology and subjective definitions of autism. The use of antidepressants by pregnant women has been associated
with autism. These and other unmetabolized psychoactive pharmaceuticals (UPPs) have also been found in drinking water
from surface sources, providing another possible exposure route and raising questions about human health consequences.
Here, we examined gene expression patterns of fathead minnows treated with a mixture of three psychoactive
pharmaceuticals (fluoxetine, venlafaxine & carbamazepine) in dosages intended to be similar to the highest observed
conservative estimates of environmental concentrations. We conducted microarray experiments examining brain tissue of
fish exposed to individual pharmaceuticals and a mixture of all three. We used gene-class analysis to test for enrichment of
gene sets involved with ten human neurological disorders. Only sets associated with idiopathic autism were unambiguously
enriched. We found that UPPs induce autism-like gene expression patterns in fish. Our findings suggest a new potential
trigger for idiopathic autism in genetically susceptible individuals involving an overlooked source of environmental
contamination.
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Introduction
Autism spectrum disorders (ASD) are characterized by stereo-
typed behaviors and impaired social skills, typically diagnosed by
three years of age [1–3]. Idiopathic ASD, caused by genetic
susceptibility factors [4–6] interacting with unknown environmen-
tal triggers [7,8], has increased dramatically in the past 25 years
[9,10]. Identifying environmental triggers has been difficult due to
the poorly understood pathophysiology of ASD and broad,
subjective case definitions.
In order to serve as such a trigger, a candidate teratogen must
have a biologically plausible etiological mechanism, exist in
sufficient environmental concentrations, be capable of passing
from mother to fetus and across the fetal blood-brain barrier (if
one assumes prenatal exposure), and have experienced historical
increases in environmental concentration parallel with observed
increases in ASD prevalence.
Coincident with the observed increase in ASD prevalence is the
introduction of modern rationally designed psychoactive pharma-
ceuticals, beginning with selective serotonin re-uptake inhibitors
(SSRIs) in 1987 (initially fluoxetine, FLX; now 9+ versions), and
serotonin–norepinephrine reuptake inhibitors (SNRIs) in 1994
(initially venlafaxine, VNX; now 8+ versions). These pharmaceu-
ticals result in an increase in the neurotransmitter serotonin, which
is responsible for the regulation of neural activity and other
physiological functions [11]. The leaky blood brain barrier of the
fetus and infants is permeable to many compounds, making this
population particularly vulnerable to the effects of serotonin.
Maternal exposure to SSRIs result in elevated fetal plasma
serotonin levels, which has been associated with autism [12]. In
other work, rat pups exposed prenatally to SSRIs exhibited
behaviors associated with ASD [13].
The use of SSRIs and SNRIs by pregnant women to treat
depression and other psychological disorders has been associated
with low APGAR (Appearance, Pulse, Grimace, Activity, Respi-
ration) scores [14], increased risk of spontaneous abortion [15],
several other consequences for children [16–20], and, recently,
ASD [21]. Several other classes of psychoactive pharmaceuticals
are also known autism risk factors when taken prenatally [22,23],
including valproic acid used to induce the autism rat model
[24,25]. Since the 1960s, for example, pregnant women have used
carbamazepine (CBZ) for control of seizures, despite its potential
association with developmental issues [26]. Studies of these drugs
considered only effects of maternal usage of clinical dosages
[21,27]; while widespread, clinical usage of antidepressants is
insufficient to account for recent increases in autism prevalence.
There is an alternative source of exposure to antidepressants:
Unmetabolized psychoactive pharmaceuticals (UPPs) found in raw
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of such facilities, and, ultimately, drinking water [28,29]. Because
concentrations are so minute (typically ng to mg?L
-1), human
health consequences of UPPs remain controversial. While the
highest observed concentrations of UPPs have biological effects in
fish [30], these concentrations are many orders of magnitude
below human clinical dosages (Table 1). While fetuses and infants
may have been exposed to UPPs through maternal water
consumption, it has been assumed that UPPs have no measurable
and enduring effects on human health [31,32]. However, multiple
related formulations and active metabolites of UPPs present in the
environment exist in complex mixtures [33,34] that together
constitute much higher dosages, especially in contamination hot-
spots [35]. Therefore, we describe the experimental concentrations
used here as similar to the highest observed environmental
concentrations, despite the fact that experimental concentrations
are an order of magnitude higher than the most recent (and
probably conservative) estimates of environmental concentrations
(Table 1).
Here, we describe results of an experiment that explores a
potential association between UPPs and idiopathic ASD. We
tested whether chronic exposure to a mixture of UPPs induced
autism-like gene expression profiles in a model organism using
gene-class analysis. We used treatments involving a mixture of
UPPs similar to that observed in aquatic systems and examined
expression of genes expressed by individuals with various forms of
idiopathic ASD. For comparison, we examined sets of genes
expressed by individuals with other neurological disorders.
Gene Expression Analysis
We exposed fathead minnows, Pimephales promelas, to FLX,
VNX, and CBZ in a 3-component mixture. FLX, VNX, and CBZ
were chosen because they represent modern pharmaceutical
classes that are highly prescribed and are among the UPPs with
the highest observed environmental concentrations (Table 1). We
conducted gene-class analysis of expression patterns induced by
the pharmaceutical treatments using Gene Set Enrichment
Analysis (GSEA) [36] and an enhanced annotation of the fathead
microarray platform [37]. The gene-class analysis approach tests if
a set of genes, described a priori, is enriched by a given treatment.
The data for the present study were derived from a previous
analysis of this system [38]. In that study, we found enrichment of
gene sets associated with neurological development, growth and
regulation by the mixture of UPPs. These genes sets were not
enriched by treatments of the pharmaceuticals administered
separately, and were associated with the formation and regulation
of neural circuits, which may indicate formation of altered and
imprecise synaptic connections and presage a failure to form
typical mature neural circuits.
In the present study, we first tested the prediction that UPPs
would induce fish gene expression profiles that mimic human
expression profiles observed in individuals diagnosed with various
neurological disorders (‘‘ND’’ sets, described in Table 2). We
tested 12 sets of genes associated with idiopathic ASD (broadly
defined), autism secondary to known genetic defects (involving
fragile X and Rett syndromes), Alzheimer’s disease, Parkinson’s
disease, schizophrenia, multiple sclerosis, major depression,
bipolar disorder and ADHD.
Second, we tested the prediction that UPPs would induce fish
gene expression profiles that mimic human expression profiles
observed in individuals diagnosed with autism of various degrees
of severity. The idiopathic autism set used above (described in
Table 2) was derived from several independent gene expression
studies with minimal overlap of gene constituents, each of which
identified genes enriched in individuals diagnosed with idiopathic
autism. One of these sets [39] was deconstructed into specific
populations classified by severity of autism symptoms. We created
a second collection consisting of 10 autism sets (‘‘ASD’’ sets;
Table 3): nine sets associated with gene expression in individuals
diagnosed with some form of autism plus a set of susceptibility
genes not associated with any known increase in gene expression
but, rather, known to have either mutations (e.g., single nucleotide
polymorphisms) or structural variations (e.g., copy number
variation) associated with some form of autism [4].
Results
In the analysis of the ND sets, seven of 12 sets were up-
regulated, with significant enrichment of the set associated with
idiopathic autism (Table 4). We also observed enrichment of two
disorders with adult onset: a set associated with Parkinson’s and
one set associated with MS (but not a second, independent MS
set). There was no overlap between the autism set and the
Parkinson’s & MS sets; 4 genes occurred in both MS and
Parkinson’s sets. No other set associated with human neurological
disorders was enriched, including secondary autism sets.
In the analysis of ASD sets, all 10 sets were up-regulated, with
significant enrichment of five of the nine expression-based sets
(Table 5). Very few genes are shared among enriched sets. The
susceptibility set was not enriched; this is significant because one
would not necessarily expect genes that underlie susceptibility to
also experience differential expression. Interestingly, one of the
strongly enriched sets (Voineagu_Down) was identified by the
study authors as genes down-regulated in individuals with autism
Table 1. Observed values of psychoactive pharmaceuticals in various systems.
Source FLX VNX CBZ
Experimental 10 mg?L
21 50 mg?L
21 100 mg?L
21
Raw sewage 0.073 mg?L
21[50] 2.19 mg?L
21[51] 6.3 mg?L
21[52]
Wastewater treatment plant (WWTP) 0.509 mg?L
21[53] 1.115 mg?L
21[47] 17.3–22.0 mg?L
21[54,55]
Effluent from WWTP 0.841 mg?L
21[56] No information 1.16 mg?L
21[57]
Downstream from WWTP 0.93 mg?L
21[55] 0.387 mg?L
21[57] 2.3 mg?L
21[47]
River system 0.12 mg?L
21[58] 1.31 mg?L
21[51] 1.283 mg?L
21[52]
Drinking water 0.014 mg?L
21[59,60] No information 0.25 mg?L
21[60,61]
FLX, VNX and CBZ are fluoxetine, venlafaxine and carbamazepine, respectively. Values reported indicate the highest observed concentrations from various systems.
Experimental treatment dosage was selected to reflect combined dosages of multiple active metabolites for each pharmaceutical.
doi:10.1371/journal.pone.0032917.t001
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enriched. The former set was endowed with an overrepresentation
of gene ontology categories associated with synapse function, while
the latter had an overrepresentation of categories associated with
immune and inflammatory response.
Normalized enrichment scores (NES; Tables 4, 5) for the
examined sets ranged from -1.172 to 1.621 for ND sets (58% up-
regulated) and 1.050 to 1.537 for ASD sets (100% up-regulated).
While the nominal p-value indicates significance of an NES, that
value is somewhat difficult to interpret. For comparison, we
analyzed 242 curated gene sets from the Molecular Signatures
Database [36] corresponding to each human cytogenetic band
that has at least one gene. In that analysis, 52% of the sets were
up-regulated, and NES values ranged from -1.70 to 1.73. Only 5%
of scores exceeded an NES of 1.40, and no set passed the false
discovery rate (FDR) threshold of 0.25.
The analyses in this report consider mainly the MIX treatment
of UPPs. For comparison, we included GSEA analysis results from
treatments consisting of the three pharmaceuticals considered
individually. As one might expect, those treatments had lower
NES values and fewer enriched sets relative to the MIX treatment
(Tables 6, 7), although the single-drug NES values involving
Parkinson’s were all higher than the MIX treatment NES values.
Discussion
We found enrichment of gene sets associated with idiopathic
ASD but not of sets involving autism diagnoses secondary to other
disorders (Rett and fragile X syndromes) known to be caused by
specific mutations. This is significant, because it indicates that
enrichment in our treatments involve only idiopathic forms of
ASD.
There was no enrichment of other neurological disorders except
MS (in one of two sets) and Parkinson’s. This is significant because
it indicates that enrichment of the idiopathic ASD set was not
simply associated with general neurological processes, pathways or
systems generally common to neurological disorders. The MS set
has a low NES (,1.40), and a second MS set (see Table 4) is not
enriched; therefore, we are not exceedingly confident in describing
that set as enriched. The other enriched non-ASD set, Parkinson’s,
is more interesting, with a convincing NES and an intriguing
potential connection to ASD involving similar phenomenology
involving brain dysfunction [41].
A number of the genes contributing to enrichment of ASD gene
sets have been implicated in other recent studies not included in
our analysis. For example, Suda et al. [42] found that relative
expression levels of EFNB3, PLXNA4 and ROBO2 were
significantly different in individuals with autism than in neuroty-
pical individuals; protein levels of PLXNA4 and ROBO2, but not
for EFNB3, were significantly reduced in brains of individuals with
autism compared to control brains. In the present study, we found
3 plexin genes (PLXNB1, PLXND1 & PLXNA3; PLXNA4 was
not on the array) and ROBO2 to be strongly down-regulated in
response to the MIX treatment, while EFNB3 and five related
genes (EFNB1, EFNA1, EFNA2, EFNA3 & EFNA5) were up-
regulated. These and other genes contributing to gene set
enrichment are associated with the formation of synapses,
perturbation of which may indicate an altered and imprecise
synaptic connections or a failure to form mature neural circuits.
The results presented here are consistent with several recent
lines of inquiry: First, the hypothesis that hyperserotonemia plays a
Table 2. ‘‘ND’’: Sets of genes associated with various human neurological disorders.
Set name Description
Number of
genes (set)
Number of
genes (FH
microarray) GEO link Reference
ASD_Idiopathic Combination of Chakrabarti, Hu & ASD_2Class; duplicates were removed
(see Table S3 for details).
–3 2 4
ADHD_up A comparison of molecular alterations in environmental and genetic rat
models of ADHD (up-regulated genes)
50 30 GSE12457 [62]
ADHD_down A comparison of molecular alterations in environmental and genetic rat
models of ADHD (down-regulated genes)
34 20 GSE12457 [62]
Rett Genes found to be up-regulated in females with Rett Syndrome 39 25 [63]
ASD_Secondary Gene expression profiles of lymphoblastoid cells from individuals with
fragile X syndrome and dup(15q).
67 39 GSE7329 [64]
Schizophrenia Proteins consistently differentially expressed in the brains of SCZ patients. 30 23 [65]
Alzheimers Up-regulated in correlation with incipient Alzheimer’s Disease, in the CA1
region of the hippocampus
345 237 GSE1297 [66]
Parkinsons Genes associated with Parkinson’s Disease. 162 94 KEGG
HSA05012
Depression Genes upregulated in major depressive disorder (p,0.05, fold change .1.4,
mean average difference .150 in at least one of the groups, called present
in greater than 20% of all samples)
45 23 GSE12654 [67]
Bipolar Genes found to be up-regulated in individuals with bipolar disorder. 71 41 [68]
MS_Bomprezzi In an attempt to identify molecular markers indicative of disease status rather
than susceptibility genes for MS, the authors show that gene expression
profiling of peripheral blood mononuclear cells by cDNA microarrays can
distinguish MS patients from healthy controls.
45 28 [69]
MS_Gilli Results showed an altered expression of 347 transcripts in non-pregnant
MS patients with respect to non-pregnant healthy controls.
348 216 GSE17393 [70]
doi:10.1371/journal.pone.0032917.t002
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involving SSRIs [27]. In that work, Hadjikhani explored a
potential role of elevated serotonin levels perturbing brain
development during pregnancy (in which he assumes that
maternal serotonin ultimately passes the fetal blood brain barrier).
The author speculated that elevated levels could be increased by
maternal use of serotonin elevating pharmaceuticals (like SSRIs) or
consumption of serotonin-rich foods. In the present study,
serotonin levels were not measured. However, all six serotonin
receptor genes on the array (HTR1A, HTR1B, HTR2C, HTR4,
HTR7& SLC6A4) were strongly down-regulated in response to
the MIX treatment. If this implies a consequential elevation of
serotonin levels, our results would seem to be consistent with the
Hadjikhani hypothesis [27] and with other recent experimental
work using model organisms [13].
Second, recent evidence supports an association of antidepres-
sants, including SSRIs, with autism [21]. In that study, Croen and
colleagues found a 2-fold increase in ASD risk associated with
SSRIs, with the strongest effect occurring in the first trimester.
The results of the present study are consistent with this finding.
However, maternal SSRI use is not sufficient to explain the
increase in prevalence of ASD.
Third, there is evidence for an unambiguous environmental
component involved in the etiology of autism [7]. In that study,
Hallmayer and colleagues provide robust evidence that, while
having a moderate genetic component, ASD also clearly involves
an environmental trigger. The results of the present study are
consistent with this finding, as is the assumption that the
environmental trigger acts in concert with genetic susceptibility.
Fourth, there is evidence of demographic changes that may
have increased the proportion of genetically susceptible individuals
Table 3. ‘‘ASD’’: Collection of sets of genes associated with idiopathic autism.
Set name Description
Number of
genes (set)
Number of
genes (FH
microarray) GEO link Reference
Pinto Genes associated with genetic susceptibility to ASD but not
known to be up- or down-regulated in the disorder.
104 63 [4]
Chakrabarti Genes related to sex steroids, neural growth, and social-emotional
behavior associated with autistic traits, empathy, and Asperger’s
syndrome. Included only mild cases (no severe language impairment).
66 43 [71]
Hu Gene identified by comparisons of neurotypical vs. ASD individuals with
severe language impairment (with individuals having specific genetic and
chromosomal abnormalities and co-morbid disorders excluded from study).
34 22 [72]
ASD_2Class Significantly differentially expressed genes from a 2-class SAM analysis
of data from combined autistic samples and neurotypical controls,
with FDR ,5%
370 240 GSE15402 [39]
ASD_Mild Significantly differentially expressed genes from a 2-class SAM analysis
of data from the group with mild ASD (M) and neurotypical controls (C ),
with FDR ,5%
360 241 GSE15402 [39]
ASD_Severe Significantly differentially expressed genes from a 2-class SAM analysis of
data from the group with severe language impairment (L) and neurotypical
controls (C ), with FDR ,0.0001%
191 121 GSE15402 [39]
ASD_Shared Common genes to all GSE15402 sets. 70 48 GSE15402 [39]
ASD_Savant Significantly differentially expressed genes from a 2-class SAM analysis of data<
Table 4. Sets associated with human neurological disorders.
Set Size NES p-value FDR q-value
AUTISM_IDIOPATHIC 324 1.621 0.000 0.064
PARKINSONS 94 1.560 0.007 0.055
MS_GILLI 216 1.375 0.011 0.137
SCHIZOPHRENIA 23 1.232 0.181 0.364
MS_BOMPREZZI 28 1.199 0.201 0.326
ADHD_UP 30 1.187 0.222 0.275
DEPRESSION 23 1.137 0.307 0.293
ADHD_DOWN 20 –0.684 0.894 0.924
RETT 25 –0.784 0.798 1.000
ALZHEIMERS 237 –0.967 0.549 0.859
ASD_SECONDARY 39 –1.083 0.332 0.764
BIPOLAR 41 –1.172 0.217 1.000
Sets are described in Table 2; size refers to the number of genes in the set; NES
is the normalized enrichment scores for the set; p-value is the nominal p-value
associated with the NES; FDR q-value is the false discovery rate ratio.
doi:10.1371/journal.pone.0032917.t004
Table 5. Analysis of sets associated with human autism.
Set Size NES p-value FDR q-value
ASD_MILD 241 1.537 0.0000 0.1261
ASD_2CLASS 240 1.519 0.0000 0.0742
VOINEAGU_DOWN 121 1.514 0.0017 0.0511
ASD_SAVANT 60 1.474 0.0298 0.0537
ASD_SHARED 48 1.459 0.0391 0.0489
CHAKRABARTI 43 1.358 0.0769 0.0864
HU 22 1.352 0.1168 0.0777
ASD_SEVERE 121 1.261 0.0781 0.1233
VOINEAGU_UP 132 1.117 0.2092 0.2749
PINTO 63 1.050 0.3558 0.3558
Column labeled as in Table 4. Sets are described in Table 3.
doi:10.1371/journal.pone.0032917.t005
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proposed that assortative mating among genetically susceptible
individuals has increased the proportion of susceptible individuals
in human populations since the 1970s. Especially when coupled
with increased levels of an environmental trigger, this would create
circumstances in which one would expect an increase in ASD
prevalence. Given that SSRIs were introduced in the mid-1980s
and SNRIs in the mid-1990s, coincident with increases in ASD
prevalence [10], the assortative mating hypothesis provides a
framework for understanding why such a trigger is able to induce
such a large effect. The results of the present study provide a
potential source of exposure to psychoactive pharmaceuticals that
does not involve maternal clinical usage of SSRIs.
Given the conserved nature (i.e., sequence and function) of the
genes involved in the observed expression profiles, and given that
the genes on the Fathead array are homologous to highly
conserved human genes, it is reasonable to expect induction of
humans gene expression profiles similar to the Fathead profiles.
This sort of approach has been effectively used for other models of
human disorders [44] and in previous investigations involving the
Fathead microarray platform [37]. Here, many of the enriched
sets involve genes associated with neuronal development and
growth [38], which is consistent with systems and pathways known
to be perturbed in the developing brain of individuals with autism
[40,45].
The concentrations used in this study were higher than
observed environmental concentrations in order to account for
conservative concentration estimates and the presence of related
formulations and active metabolites [29,34,46,47]. Future work
needs to be conducted to measure the concentrations of all UPP
constituents present in aquatic systems and drinking water (with
appropriate temporal and geographic sampling) in order to
accurately assess human exposure and health consequences.
Conclusions
These results provide a new perspective on the etiology of
idiopathic ASD and suggest new directions for research into
Table 6. Single drug treatments & ASD sets.
FLX FLX FLX VNX VNX VNX CBZ CBZ CBZ
Set NES p-value FDR q-value NES p-value FDR q-value NES p-value FDR q-value
ASD_SAVANT 1.443 0.036 0.144 1.344 0.075 0.174 1.287 0.103 0.138
ASD_MILD 1.429 0.003 0.081 1.370 0.018 0.215 1.531 0.000 0.099
ASD_SHARED 1.362 0.066 0.089 1.331 0.088 0.143 1.115 0.244 0.322
ASD_2CLASS 1.290 0.022 0.118 1.411 0.005 0.289 1.490 0.002 0.076
ASD_SEVERE 1.199 0.115 0.172 0.979 0.514 0.634 1.342 0.039 0.155
CHAKRABARTI 1.144 0.246 0.206 0.887 0.662 0.695 1.017 0.432 0.475
VOINEAGU_DOWN 20.837 0.831 0.809 1.116 0.220 0.443 1.288 0.054 0.172
VOINEAGU_UP 20.899 0.701 0.906 20.909 0.716 0.670 -1.018 0.404 0.415
PINTO 21.061 0.339 0.677 1.018 0.420 0.627 -1.065 0.337 0.659
HU 21.378 0.080 0.150 0.901 0.582 0.747 0.893 0.591 0.697
FLX, VNX and CBZ are fluoxetine, venlafaxine and carbamazepine, respectively. Column labeled as in Table 4. Sets are described in Table 3.
doi:10.1371/journal.pone.0032917.t006
Table 7. Single drug treatments & ND sets.
FLX FLX FLX VNX VNX VNX CBZ CBZ CBZ
Set NES p-value FDR q-value NES p-value FDR q-value NES p-value FDR q-value
PARKINSONS 1.650 0.000 0.058 1.780 0.000 0.011 2.110 0.000 0.000
AUTISM_IDIOPATHIC 1.505 0.000 0.219 1.412 0.004 0.390 1.5104 0.0000 0.1930
RETT 1.164 0.237 0.738 1.079 0.338 0.452 0.7529 0.8097 0.8795
SCHIZOPHRENIA 1.104 0.316 0.661 1.164 0.251 0.497 1.2040 0.2079 0.2905
ADHD_UP 1.102 0.327 0.501 1.155 0.243 0.390 1.5102 0.0397 0.0965
MS_GILLI 0.997 0.500 0.639 1.364 0.017 0.265 1.0616 0.2827 0.4790
MS_BOMPREZZI 0.904 0.589 0.755 0.857 0.687 0.732 0.9935 0.4295 0.5343
ASD_SECONDARY 0.631 0.974 0.965 –0.749 0.896 0.870 –0.622 0.970 0.968
BIPOLAR –0.774 0.832 0.856 –1.401 0.047 0.300 –0.812 0.773 1.000
ALZHEIMERS –1.118 0.204 0.447 –0.847 0.906 0.928 –0.934 0.640 0.969
DEPRESSION –1.170 0.248 0.523 0.919 0.583 0.717 1.2313 0.1871 0.3349
ADHD_DOWN –1.715 0.004 0.019 –1.375 0.110 0.177 –1.322 0.152 0.465
FLX, VNX and CBZ are fluoxetine, venlafaxine and carbamazepine, respectively. Column labeled as in Table 4. Sets are described in Table 2.
doi:10.1371/journal.pone.0032917.t007
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expression study indicate that a mixture of UPPs can induce an
ASD-like gene expression profile in a model organism. Using a
low-cost model system like fathead minnow, researchers can
rapidly screen potential teratogens for their ability to induce ASD-
like gene expression patterns in developing brains. In order to
clearly determine if UPPs are associated with idiopathic ASD in
humans, future work needs to examine a wider palette of UPPs
(and other potential teratogens) and results need to be validated by
demonstrating treatment response in another model systems. This
could involve using a mouse model, with which one could measure
fetal brain expression patterns, UPP concentration in fetal blood,
and concentrations of fetal neurohypophyseal hormones, following
maternal treatment. Further, epidemiological studies at the
individual patient level should be conducted to confirm and
specify the relationship between environmental contaminants and
ASDs. The mimicry of ASD-like gene expression profiles in fish,
described above, does not conclusively indicate UPP induction of
ASD in humans. It does, however, serve as the basis for new
hypotheses regarding the etiology of idiopathic ASD.
Materials and Methods
Ethics Statement
All fish handling and treatments were performed at the Great
Lakes WATER Institute (School of Freshwater Sciences, Univer-
sity of Wisconsin-Milwaukee, Milwaukee, Wisconsin) using
appropriate UWM Institutional Animal Care and Use Committee
(IACUC) approved protocols (approval number 0708#14).
Fish Treatments
Full details of the fish treatments are described in a previous
report [38]. Briefly, three 2-gallon tanks were used for each
pharmaceutical treatment along with three tanks for a mixture
treatment (containing all three pharmaceuticals in the concentra-
tions listed in Table 1) and three tanks for control (containing no
pharmaceuticals). Each tank housed five juvenile fathead min-
nows. Dosages of pharmaceuticals were re-administered with each
change of the tank water (every 2 days). Fish were exposed to
treatments for eighteen days.
Gene Set Enrichment Analysis
Fish mRNA was pooled within a tank for microarray work (for
3 replicates per treatment) but not for qPCR validation (for 15
replicates per treatment). Details of microarray experiments,
including validation by qPCR analysis of 9 genes with high rank
correlation and all data files, are described in a previous report
[38]. Microarray experiments conformed to MIAME guidelines
and results were deposited in GEO (GSE22261).
The previous study [38] also described an altered phenotype
associated with pharmaceutical treatment that involved measur-
ing fish behavior in response to a startle stimulus modeled after
predator avoidance behavior used elsewhere [49]. We found that
fish behavior was indicative of a neurologically relevant
phenotype: following a ‘‘startle,’’ the distance traveled and
number of direction changes both significantly increased for
treated fish [38].
Here, two groups of gene sets gene-class analyses were
conducted: ND (‘‘neurological disorder’’) and ASD (‘‘autism
spectrum disorder’’). The gene sets in the ND collection, known
to be associated with a variety of human neurological disorders,
are described in Table 2. The gene sets in the ASD collection,
associated with enriched gene expression in autism, are described
in Table 3. Both gene sets are provided in Supporting
Information (Table S1, ‘‘ND gene list,’’ and Table S2, ‘‘ASD
gene list’’). Each group consisted of a collection of gene sets, with
each set tested against the ranked list of genes reflecting signal-to-
noise ratio of MIX treatment (combining FLX, VNX & CBZ)
relative to control. Additional comparisons between the control
and treatments consisting of the three pharmaceuticals consid-
ered individually were included for comparison (Tables 6, 7).
Gene-class analyses used GSEA release 2.06 and MSigDB
release 2.5. Weighted enrichment scores were calculated using
gene expression lists ranked by signal-to-noise ratio. The genes
on the array were ranked by correlation between the MIX and
CTL treatments (those genes with the strongest up-regulation in
treatment relative to control were ranked highest; those with
strongest down-regulation were ranked lowest). (See Table S3,
‘‘Ranked gene list,’’ for these data.) The maximum gene set size
was set to 500 genes; the minimum gene set size was set to 10
genes; the number of permutations was set to 1000. Permutations
were conducted by gene set (rather than by phenotype). For
details of GSEA parameter usage, see Subramanian et al. [36].
Gene sets were examined to ensure they contained only
GSEA-recognized primary HUGO symbols, rather than aliases
or unapproved symbols. This was accomplished through the use
of a custom script that compared each gene in a given set to the
GENE_SYMBOLS.chip file (from GSEA) containing a list of
HUGO symbols with accepted aliases. Gene set components
listed as aliases in this file were replaced with the appropriate
HUGO symbol. For additional details of the annotation and
GSEA implementation using the EcoArray 15k Fathead Minnow
arrays, see Thomas et al. [37].
Supporting Information
Table S1 ND gene list. A list of the neurological disorders
gene sets, in the GSEA gene matrix (.GMX) file format.
(GMX)
Table S2 ASD gene list. A list of the autism spectrum
disorders gene sets, in the GSEA gene matrix (.GMX) file format.
(GMX)
Table S3 Ranked gene list. A Microsoft Excel spreadsheet
containing all annotated array gene elements sorted by signal-to-
noise ratio for the mixture v. control comparison.
(XLS)
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